Investing.com -- TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry Genetics.
The brokerage said the deal accelerates Tempus' path to profitability, with Ambry expected to generate more than $40 million in EBITDA in 2024. The acquisition also expands Tempus' database by integrating Ambry’s germline testing business, creating new product opportunities and potential synergies.
“The deal affords TEM profitable germline testing lab, offers opportunities to enhance TEM's existing products, expand into new areas&provides path to positive free cash flow, w/ the main drawback Ambry's slower growth,” analyst at TD said, highlighting a larger revenue base&attractive growth/margin expansion.
However, TD Cowen noted that Ambry's long-term revenue growth of about 20% per year is below Tempus' standalone growth rate, slightly diluting its overall expansion trajectory. The deal also brings integration and execution risks.
Ambry, a 25-year-old genetics testing firm, is expected to generate over $300 million in revenue this year, with growth boosted by market share gains following Invitae’s bankruptcy.
Related Articles
TD Cowen reinstates coverage on Tempus AI with 'buy' after Ambry deal
Parker-Hannifin ratings upgraded by Moody's, positive outlook maintained
Japan Airlines jet wing strikes Delta Air plane on ground in Seattle
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。